|
Jul 25
|
GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan
|
|
Jun 26
|
Senior VP & Chief Medical Officer of GlycoMimetics Edwin Rock Buys 81% More Shares
|
|
May 8
|
Uproleselan’s failed Phase III AML trial shakes up GlycoMimetics’ future
|
|
May 7
|
GlycoMimetics reports data from Phase III AML treatment trial
|
|
May 6
|
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
|
|
Apr 28
|
We're Keeping An Eye On GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate
|
|
Apr 25
|
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
|
|
Apr 1
|
Loss-Making GlycoMimetics, Inc. (NASDAQ:GLYC) Expected To Breakeven In The Medium-Term
|
|
Mar 28
|
GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call Transcript
|
|
Mar 28
|
Q4 2023 GlycoMimetics Inc Earnings Call
|
|
Mar 27
|
GlycoMimetics Inc (GLYC) Posts Quarterly Loss, Aligns with Analyst Projections
|
|
Mar 27
|
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
|
|
Mar 21
|
Should You Buy GlycoMimetics (GLYC) Ahead of Earnings?
|
|
Mar 13
|
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
|
|
Mar 4
|
Positive Signs As Multiple Insiders Buy GlycoMimetics Stock
|
|
Dec 10
|
GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia
|
|
Jun 26
|
GlycoMimetics Announces Its Addition to the Russell Microcap® Index
|
|
Apr 26
|
GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023
|